On Dec. 8, 2025, Eli Lilly increased its dividend by 15.33%, from $1.50 to $1.73 per share. The dividend is payable on March 10, 2026 to shareholders of record on Feb. 13, 2026.
The U.S. stock market is currently experiencing a striking divergence in performance, with the venerable Dow Jones Industrial Average and the broad-based S&P 500 Index ascending to unprecedented record highs, while the technology-heavy Nasdaq Composite finds itself struggling in their wake. This "Great Divergence," observed around December 12,
The venerable Dow Jones Industrial Average (DJIA) has once again captured headlines, surging to unprecedented intraday record highs around December 2025. This remarkable ascent, which saw the blue-chip index breach the 48,000 mark in November and reach a new peak of 48,704 on December 11, 2025, continuing its
The financial markets roared to an emphatic close on December 11, 2025, with major indices shattering previous records in a session defined by widespread optimism and robust investor confidence. This monumental surge, fueled by a potent cocktail of stronger-than-expected corporate earnings, encouraging inflation data, and a perceived dovish pivot from
As December 2025 unfolds, global financial markets are characterized by a delicate balance of cautious optimism and persistent uncertainty. A "Santa Claus rally" sentiment prevails, fueled by expectations of central bank easing and a surprisingly resilient, albeit slowing, global economy. While the technology sector continues its role as a primary
The financial markets in late 2025 present a complex narrative, a tug-of-war between the long-reigning titans of growth and a resurgent, yet often overshadowed, cohort of value stocks. While the year-to-date performance figures as of December 11, 2025, still crown growth equities as the overall victors, a closer look reveals
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 3.4% in the morning session after the company announced highly positive Phase 3 trial results for its next-generation weight loss candidate, retatrutide.
Eli Lilly and Company (NYSE: LLY) has once again sent ripples through the pharmaceutical world with the announcement of groundbreaking Phase 3 trial results for its investigational obesity drug, retatrutide. The data, particularly from the TRIUMPH-4 study, reveals unprecedented levels of weight loss and significant improvements in co-morbidities like knee
Small-capitalization stocks are currently experiencing an unprecedented surge, with the benchmark Russell 2000 index shattering all-time records in early December 2025. This remarkable rally, which saw the index climb over 13% year-to-date, signifies a profound shift in investor sentiment and a significant rebalancing of capital away from the long-dominant technology
New York, NY – December 10, 2025 – The U.S. stock market is currently experiencing a robust rally, with major indices positioned tantalizingly close to their all-time highs. This bullish sentiment, culminating in a significant surge on December 10, 2025, is largely propelled by the Federal Reserve's recent interest rate cut
